[go: up one dir, main page]

MX2018005547A - Compuestos polimericos sol-gel y sus usos. - Google Patents

Compuestos polimericos sol-gel y sus usos.

Info

Publication number
MX2018005547A
MX2018005547A MX2018005547A MX2018005547A MX2018005547A MX 2018005547 A MX2018005547 A MX 2018005547A MX 2018005547 A MX2018005547 A MX 2018005547A MX 2018005547 A MX2018005547 A MX 2018005547A MX 2018005547 A MX2018005547 A MX 2018005547A
Authority
MX
Mexico
Prior art keywords
sol
gel
response
nipple
compound
Prior art date
Application number
MX2018005547A
Other languages
English (en)
Other versions
MX374683B (es
Inventor
Stephen L Secreast
A Zook Christopher
R Quesnell Rebecca
Rajagopalan Sumitra
Baille Wilms
Kujawa Piotr
L Czek Dennis
Luo Laibin
A Sanders Tammy
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2018005547A publication Critical patent/MX2018005547A/es
Publication of MX374683B publication Critical patent/MX374683B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

En general, la presente descripción se refiere a compuestos poliméricos sol-gel que comprenden quitosano, un polímero hidrófilo, un agente de gelificación e ingredientes adicionales opcionales en un medio adecuado; de manera ventajosa, el compuesto polimérico sol-gel puede formar un sello duradero o un sólido fuerte en respuesta a uno o más estímulos fisiológicos; la descripción también se refiere a usos médicos y veterinarios del compuesto, en particular, métodos y sistemas de administración para reducir o prevenir la incidencia de un trastorno mamario en un animal lechero; más en particular, la descripción incluye métodos y composiciones de compuestos poliméricos sol-gel para crear una barrera física en la superficie del pezón o en el canal o la cisterna del pezón de un animal no humano para el tratamiento profiláctico de trastornos mamarios, tales como mastitis, en donde el polímero sol-gel crea un sello en respuesta a uno o más estímulos fisiológicos.
MX2018005547A 2015-11-03 2016-11-02 Compuestos polimericos sol-gel y sus usos. MX374683B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250126P 2015-11-03 2015-11-03
US201662315756P 2016-03-31 2016-03-31
PCT/US2016/060015 WO2017079216A1 (en) 2015-11-03 2016-11-02 Sol-gel polymer composites and uses thereof

Publications (2)

Publication Number Publication Date
MX2018005547A true MX2018005547A (es) 2018-11-09
MX374683B MX374683B (es) 2025-03-04

Family

ID=57471981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005547A MX374683B (es) 2015-11-03 2016-11-02 Compuestos polimericos sol-gel y sus usos.

Country Status (16)

Country Link
US (2) US10064870B2 (es)
EP (1) EP3370698B1 (es)
JP (1) JP6864001B2 (es)
KR (1) KR102145435B1 (es)
CN (1) CN108601723B (es)
AU (1) AU2016350868B2 (es)
BR (1) BR112018009010B1 (es)
CA (1) CA3002214C (es)
CL (1) CL2018001194A1 (es)
ES (1) ES2907686T3 (es)
MX (1) MX374683B (es)
PL (1) PL3370698T3 (es)
PT (1) PT3370698T (es)
RU (1) RU2761212C2 (es)
UY (1) UY36973A (es)
WO (1) WO2017079216A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RU2018135961A (ru) * 2016-03-18 2020-04-20 Министерство Сельского Хозяйства И Сельскохозяйственной Продукции Ее Величества Королевы Канады По Праву Способ ускорения инволюции и предотвращения инфекции молочной железы дойного животного при запуске
SG11201808270PA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
DK3436435T3 (da) 2016-03-31 2021-08-09 Janssen Pharmaceuticals Inc Substituerede indolderivater som inhibitorer af replikation af denguevirus
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018011786A (es) 2016-04-01 2019-05-20 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue.
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP7123971B2 (ja) * 2017-04-20 2022-08-23 ゾエティス・サービシーズ・エルエルシー 乳腺炎を処置する際に使用する動物用組成物、及び関連方法
WO2018215315A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2018215316A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
AU2018280866A1 (en) * 2017-06-09 2019-12-12 Zoetis Broomhill Ip Limited Intramammary veterinary composition
CN109575484A (zh) * 2017-09-29 2019-04-05 天津城建大学 新型埃洛石/聚乙烯醇复合气凝胶及其制备方法和应用
CN111629766A (zh) * 2017-12-01 2020-09-04 硕腾服务有限责任公司 水凝胶组合物及其用途
CN111801068A (zh) * 2018-01-18 2020-10-20 硕腾布鲁姆希尔Ip有限公司 内部乳头密封剂及其在预防干奶牛的牛乳腺炎中的应用
US20210299157A1 (en) * 2018-08-06 2021-09-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Cellulose-based topical formulations
JP6882744B2 (ja) * 2018-11-22 2021-06-02 学校法人自治医科大学 内視鏡の視野確保用の粘弾性組成物
EP3897134B1 (en) * 2018-12-14 2025-01-08 Ecolab USA Inc. Stable iodine-containing antimicrobial teat dip compositions
CN110437471B (zh) * 2019-07-11 2022-02-15 郑州轻工业学院 一种粘性复合水凝胶及其制备方法和用途
CN115003626A (zh) * 2019-12-20 2022-09-02 威利纳米有限公司 纳米结构二元凝胶组合物及其用途
CN111012947B (zh) * 2019-12-30 2021-11-12 南京财经大学 一种可注射和自愈合淀粉基水凝胶及其制备方法和应用
CN111214699A (zh) * 2020-01-08 2020-06-02 广州贝奥吉因生物科技股份有限公司 一种用于周围神经损伤修复的水凝胶及其制备方法
CN111840212B (zh) * 2020-06-18 2023-07-21 余祖功 一种非人类动物用乳头封闭剂及其制备方法
CN111825858B (zh) * 2020-07-02 2023-04-25 南京师范大学 一种基于两性离子和角蛋白的复合水凝胶及其制备方法
CN116157138A (zh) * 2020-09-11 2023-05-23 联邦高等教育系统匹兹堡大学 源自细胞外基质的最终灭菌的水凝胶或胶体悬浮液的制备方法及其用途
WO2022217069A1 (en) * 2021-04-09 2022-10-13 Colorado School Of Mines Radical crosslinked zwitterionic gels and uses thereof
BR112023022624A2 (pt) * 2021-04-28 2024-01-16 Mileutis Ltd Composições e métodos para modular distúrbios e condições mamárias
CN113736435B (zh) * 2021-10-08 2023-05-12 扬州工业职业技术学院 一种钻井液用纳米微乳液封堵剂及其制备方法
CN114539574B (zh) * 2022-02-28 2023-06-06 浙江农林大学 压电-摩擦电耦合感应材料的制备方法和应用
CN115990275A (zh) * 2022-10-08 2023-04-21 江苏省人民医院（南京医科大学第一附属医院） 一种黏膜下注射剂及其制备方法
CN115645635A (zh) * 2022-10-24 2023-01-31 杭州旸顺医疗科技有限公司 一种液相栓塞剂及其制备方法和用途
CN115804870B (zh) * 2022-12-02 2023-12-19 浙江大学 一种微创注射生物支架及其制造方法与应用
JP2025541136A (ja) * 2022-12-06 2025-12-18 トリコル バイオメディカル， インコーポレイテッド 溶解に耐える流動性キトサン生体接着性止血組成物
CN117362139A (zh) * 2023-10-27 2024-01-09 湖北航天化学技术研究所 一种提高电控固体推进剂力学性能的方法
WO2025160219A1 (en) * 2024-01-23 2025-07-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and compositions for treating reperfusion injury following myocardial infarction

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4333484A (en) 1978-08-02 1982-06-08 Philip Morris Incorporated Modified cellulosic smoking material and method for its preparation
US6074663A (en) 1995-01-16 2000-06-13 Baxter International Inc. Method of using cross-linked fibrin material
ES2183223T5 (es) 1996-12-18 2015-05-07 Bimeda Research & Development Limited Composición intramamaria para uso veterinario que no contiene agentes antiinflamatorios
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
WO2001036000A1 (en) 1999-11-15 2001-05-25 Bio Syntech Canada, Inc. Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
EP1237585B1 (en) 1999-12-09 2003-06-18 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20040047892A1 (en) 2000-11-15 2004-03-11 Desrosiers Eric Andre Filler composition for soft tissue augmentation and reconstructive surgery
EP1424995B1 (en) 2001-09-10 2010-07-14 Bimeda Research And Development Limited A bio-security system
KR100474945B1 (ko) 2002-01-10 2005-03-10 알앤엘생명과학주식회사 젖소의 원유 중 체세포 감소용 및 유방염의 예방 또는치료용 조성물
JP2007500692A (ja) * 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 乳房炎及び耳障害を治療するための分散性医薬組成物
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
AU2005207684B2 (en) 2004-02-02 2009-12-17 Zoetis Broomhill Ip Limited Method and device for treating a teat canal of an animal
US20050191270A1 (en) 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
AU2005324915A1 (en) * 2005-01-13 2006-07-20 Cinvention Ag Composite materials containing carbon nanoparticles
AU2006210267A1 (en) * 2005-02-03 2006-08-10 Cinvention Ag Drug delivery materials made by sol/gel technology
US9205046B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8323683B2 (en) 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
WO2007066837A1 (en) 2005-12-06 2007-06-14 Lg Household & Health Care Ltd. Delivery system for tooth whitening component using in situ gelling
WO2008005427A2 (en) 2006-06-30 2008-01-10 Biomimetic Therapeutics, Inc. Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
NZ549249A (en) 2006-08-18 2009-10-30 Univ Massey Methods for reducing the incidence of mastitis by administration of keratin
US7906138B2 (en) 2006-10-10 2011-03-15 Wisconsin Alumni Research Foundation Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
WO2008152444A2 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
CA2672495C (en) * 2006-12-11 2017-01-17 Chi2Gel Ltd. Novel injectable chitosan mixtures forming hydrogels
US8153612B2 (en) 2006-12-11 2012-04-10 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US9034348B2 (en) 2006-12-11 2015-05-19 Chi2Gel Ltd. Injectable chitosan mixtures forming hydrogels
US20090068255A1 (en) 2007-04-30 2009-03-12 Betty Yu Use of matrix metalloproteinase inhibitors in skin care
CN101077377A (zh) * 2007-05-09 2007-11-28 史义林 防治牛、羊乳房炎的复方碘化壳聚糖涂膜剂及其制备方法
US20090081173A1 (en) 2007-08-10 2009-03-26 The Board Of Regents Of The University Of Texas System Methods and compositions involving bacteriophage isolates
GB2461186B (en) * 2008-04-21 2010-09-01 Otonomy Inc Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CN102223876A (zh) * 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
EP2369937B1 (en) * 2008-12-04 2016-11-02 Merial, Inc. Intramammary teat sealant
WO2010065908A2 (en) * 2008-12-05 2010-06-10 Catchmark Jeffrey M Degradable biomolecule compositions
CA2746699C (en) 2008-12-16 2017-10-24 Carlsberg A/S Cellulose based polymer material
EP2376106A4 (en) 2008-12-19 2013-01-09 Biomimetic Therapeutics Inc BONE TRANSPLANTS WITH REDUCED PROTEASE EFFECT AND SELECTION AND APPLICATION PROCEDURES
WO2011022070A2 (en) 2009-08-20 2011-02-24 The Regents Of The University Of California Perivascular stem cell composition for bone
CN101664381A (zh) * 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛乳房炎的原位凝胶缓释制剂的制备方法
CN102125516B (zh) * 2010-01-13 2014-03-26 北京大学 温敏型原位凝胶药物组合物
US9301976B2 (en) 2010-08-19 2016-04-05 The Regents Of The University Of California Compositions comprising perivascular stem cells and nell-1 protein
US20130287930A1 (en) 2010-12-16 2013-10-31 Specialites Pet Food Method for producing highly palatable dry cat food
GB201113606D0 (en) 2011-08-05 2011-09-21 Norbrook Lab Ltd Dual chamber syringe
US20130108670A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
WO2013062995A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating deep partial and full thickness wounds and injuries
EP2917299A4 (en) 2012-11-09 2016-06-29 Bioastra Technologies Inc NANOSTRUCTURED PHASE SWITCHING MATERIALS FOR SOLID WATER HEAT MANAGEMENT
RU2521401C1 (ru) * 2012-12-07 2014-06-27 ГНУ Краснодарский научно-исследовательский ветеринарный институт Российская академия сельскохозяйственных наук (Краснодарский НИВИ) Средство для профилактики мастита у дойных коров в сухостойный период
KR102276326B1 (ko) 2013-03-13 2021-07-13 앙테이스 에스.아. 피부 회춘을 위한 펩타이드 및 이것을 사용하는 방법
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP7000021B2 (ja) * 2013-03-15 2022-01-19 ジェンザイム・コーポレーション アミン官能性ポリアミド
EP3038621B1 (en) 2013-03-15 2020-12-02 Human Biomolecular Research Institute Compounds and matrices for use in bone growth and repair
TW201532621A (zh) 2013-04-22 2015-09-01 Neocutis Sa 抗氧化劑組成物及其使用方法
CN103381139A (zh) 2013-05-10 2013-11-06 南京农业大学 黄芪多糖注射用原位凝胶及其制备方法
BR112016005795B1 (pt) 2013-09-16 2022-07-12 Zoetis Services Llc Conjunto de infusão
CN104510729A (zh) 2013-09-26 2015-04-15 黄永 激活动物免疫抗性的脂肪酸及其衍生物的组合物
JP7303612B2 (ja) 2014-10-03 2023-07-05 サイトリ・セラピューティクス株式会社 熱傷の進行の緩和ならびに皮膚移植片の取り込みおよび治癒の改善における再生細胞の使用

Also Published As

Publication number Publication date
AU2016350868A1 (en) 2018-05-10
BR112018009010A8 (pt) 2019-02-26
US10729698B2 (en) 2020-08-04
CN108601723B (zh) 2022-05-17
RU2018115574A (ru) 2019-10-25
US20170119785A1 (en) 2017-05-04
US10064870B2 (en) 2018-09-04
UY36973A (es) 2017-06-30
BR112018009010B1 (pt) 2023-09-26
JP2018536708A (ja) 2018-12-13
KR20180075646A (ko) 2018-07-04
RU2018115574A3 (es) 2020-03-13
KR102145435B1 (ko) 2020-08-18
BR112018009010A2 (pt) 2018-10-30
RU2761212C2 (ru) 2021-12-06
PL3370698T3 (pl) 2022-04-25
WO2017079216A1 (en) 2017-05-11
EP3370698B1 (en) 2022-01-26
CN108601723A (zh) 2018-09-28
MX374683B (es) 2025-03-04
CA3002214A1 (en) 2017-05-11
CL2018001194A1 (es) 2019-05-17
PT3370698T (pt) 2022-03-02
ES2907686T3 (es) 2022-04-26
AU2016350868B2 (en) 2022-03-31
JP6864001B2 (ja) 2021-04-21
CA3002214C (en) 2022-01-04
EP3370698A1 (en) 2018-09-12
US20190030043A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2018005547A (es) Compuestos polimericos sol-gel y sus usos.
UY37687A (es) Composiciones veterinarias para uso en tratamiento de mastitis y métodos asociados
MX2016015326A (es) Combinacion, composicion y metodo de administracion de la combinacion o composicion a animales.
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
BR112016013684A2 (pt) Solução aquosa ou hidrocoloide, método para aumentar a viscosidade de uma composição e método para o tratamento de um material
MX2016006060A (es) Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños.
BR112016028510A2 (pt) dispositivo de aplicação de agente terapêutico com lúmen convergente
CL2018000033A1 (es) Composición para destapar una nariz tapada que tiene actividad antiviral.
ECSP18026800A (es) Una composición para la acuicultura
MX2016011132A (es) Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r.
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
CL2015002319A1 (es) Dispositivo y sistema para el tratamiento de peces.
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
AR132714A2 (es) Formulación de hidrogel con adhesión moderada
JP2016535794A5 (ja) 急速崩壊性固体剤形
CL2017001245A1 (es) Metodo para tratar, prevenir o reducir el riesgo de infección cutánea
BR112015020089A2 (pt) Formulação aquosa de tratamento de semente, formulação pesticida aquosa, e, método para preparar uma formulação
MX2017009247A (es) Un metodo para la activacion de bacterias de acido lactico.
CL2013002107A1 (es) Uso de un fluido viscoelastico acuoso para producir un producto medicinal para el tratamiento quirurjico del ojo, que comprende a) por lo menos un polimero de aumento de la viscosidad a una concentracion de 0,01-30%, b) un valor de ph que oscila de 6 a 8,5 y c) una osmolaridad que oscila de 200 a 400 mosmol/l.
CR20150567A (es) Revestimientos reticulados suministrados mediante un balón
HK1256814A1 (zh) 用於在药物中使用的胶体颗粒
MX384517B (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
MX2017007567A (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales.
WO2019035143A3 (en) Medicated honey and method of preparation thereof

Legal Events

Date Code Title Description
FG Grant or registration